rf-fullcolor.png

 

May 19, 2025
by Jason Scott

Recon: Novavax nabs narrowed FDA approval for COVID-19 vaccine; FDA clears first blood test for Alzheimer’s

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US
  • Inside the rise of Tracy Beth Høeg, the Covid contrarian shaping FDA vaccine policy (STAT)
  • Novavax wins narrowed approval for its Covid-19 shot after delay (STAT)
  • Does the CDC have an acting director? (STAT)
  • HHS can require approval for drugmakers to apply 340B rebate models, court rules (Endpoints)
  • Deputy FDA chief mulls shaking up PDUFA reauthorization structure (Endpoints)
  • Trump Tax Bill Advances After Deal for Faster Medicaid Cuts (Bloomberg)
  • Bayer US head says FDA chief reassured pharma executives of timely reviews (Reuters)
In Focus: International                                                                                                       
  • People in 70 countries are missing out on medical care amid funding cuts, says WHO (Reuters)
  • Alzheimer’s Drugs Arrive in Taiwan to a Host of Questions (Bloomberg)
  • Covid Test, Vaccine Maker Stocks Jump as Cases Surge in Asia (Bloomberg)
  • Bringing Israeli Medical Device Candidates To The Right Partners In The US (MedTech Insight)
Pharma & Biotech
  • Investment firm RA Capital lays off incubator staff amid industry instability, push into China (STAT)
  • Regeneron to buy 23andMe out of bankruptcy for $256 million (STAT) (Reuters)
  • David Liu, Sam Sternberg unveil new CRISPR tech for large gene insertion (Endpoints)
  • Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026 (Endpoints)
  • Ionis details late-stage data for heart drug; Armata’s promising staph infection therapy (Endpoints)
  • Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule (Endpoints)
  • Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers (Endpoints)
Medtech
  • Eisai Shares Rise as New Alzheimer’s Test Seen Helping Sales (Bloomberg)
  • FDA clears first blood test to aid Alzheimer’s diagnosis (MedTech Dive)
  • EndoQuest, Virtuoso begin clinical trials for surgical robots (MedTech Dive)
  • Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products (MedTech Dive)
  • Siemens Healthineers invests $150M in US, moves production from Mexico (MedTech Dive)
  • Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show (MedTech Insight)
  • How Structured Patient Engagement Gives Medtech Companies A Competitive Edge (MedTech Insight)
Food & Nutrition
  • Brazil can no longer export poultry and meat to EU due to bird flu (Reuters)
  • Brazil hopes China, other countries may loosen trade bans over bird flu (Reuters)
  • FDA to revisit approval of food chemicals that ‘concern consumers most’ (Food Dive)
  • It’s a Bird, It’s a Plane, It’s an UPDATE on Operation Stork Speed (FDA Law Blog)
Government, Regulatory & Legal
  • There is no replacement (yet) for animal models in medical research (STAT)
  • The end to animal testing marks the beginning of better biomedicine (STAT)
  • UnitedHealth said it was too dangerous for him to be discharged. Days later, it denied his care (STAT)
  • Trump is moving to terminate hundreds of federal grants across Harvard (STAT)
  • Scientists are pushing to get their grants reinstated — and some are winning (STAT)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.